Governments have signed agreements with major pharmaceutical companies to make the vaccine available to the public once approved for emergency use.
Vaccination against COVID-19 started a few weeks ago in countries like Mexico, Colombia, and Argentina. With hopeful thinking to reduce the region’s death rate and achieve the much desired “herd immunity” that would allow us, in theory, to return to activities and regular daily lives.
The three vaccines’ differences are efficacy, safety, and effectiveness. Individuals’ differences are due to differences in age, gender, gender, age group, race, ethnicity, education, physical activity, and other factors.
Three Covid-19 Vaccines in America
Pfizer’s BioNtech Moderna vaccine is based on a 20-year-old technology used to treat various cancers. This involves using messenger RNA, which teaches cells in the human body in a straightforward way to produce a protein that causes the immune system to react appropriately to the SARSCov2 virus responsible for COVID-19.
Pfizer’s vaccine’s big problem is that it must be stored for a long time (Moderna can be kept at temperatures of 8 degrees C for up to 30 days) and must either be frozen or begged. According to the FDA, vaccinations have a high risk of side effects such as diarrhea, nausea, vomiting, fever, and diarrhea.
In the case of AstraZeneca’s vaccine, a genetically modified virus (coronavirus protein) is used to activate the body’s immune response. Sputnik V uses a more traditional method. Using a watered-down version of the virus, the price has risen compared to other options. It uses the same procedure as the other two vaccines but at a much higher price of $2,000.
It is easier and cheaper to produce and transport and survives up to six months. But at a much higher price of $2,000.
The efficacy is lower than Pfizer’s Moderna but can achieve 90 percent with the right conditions. In the US, efficacy rates reach 70% in the first six months, with an average survival rate of more than two years.
The four vaccines already in use in various Latin American countries are not the only ones expected this year. Sinovac and Sanofi of Johnson & Johnson are developing other proposals, while China is also developing its vaccine.
Warning Of Catastrophic Moral Failure
The head of the World Health Organization said Monday the equitable distribution of coronavirus vaccines is at “serious risk.”
Warning of a “catastrophic moral failure,” WHO’s Director-General Tedros Adhanom Ghebreyesus announced, “the recent emergence of rapidly-spreading variants makes the rapid and equitable rollout of vaccines all the more important.”
While more than 39 million doses of multiple different vaccines have now been administered in at least 49 higher-income countries, the report stated that just 25 doses were given in one lowest-income country.
Wealthier places have been accused of “hoarding” more vaccines than they need; however, the supply of vaccines is still in its early days. As mass inoculation drives began in the West during December — are still in their first distribution stage.
Access to top treatment centers